These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 3183496)
1. Standard assays underestimate the concentration of heparin in neonatal plasma. Schmidt B; Mitchell L; Ofosu F; Andrew M J Lab Clin Med; 1988 Nov; 112(5):641-3. PubMed ID: 3183496 [TBL] [Abstract][Full Text] [Related]
2. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Kitchen S; Theaker J; Preston FE Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006 [TBL] [Abstract][Full Text] [Related]
3. Antithrombin III in full-term and pre-term newborn infants: three cases of neonatal diagnosis of AT III congenital defect. De Stefano V; Leone G; De Carolis MP; Ferrelli R; De Carolis S; Pagano L; Tortorolo G; Bizzi B Thromb Haemost; 1987 Jun; 57(3):329-31. PubMed ID: 3660333 [TBL] [Abstract][Full Text] [Related]
4. Anticoagulant effects of heparin in neonatal plasma. Schmidt B; Ofosu FA; Mitchell L; Brooker LA; Andrew M Pediatr Res; 1989 Apr; 25(4):405-8. PubMed ID: 2726317 [TBL] [Abstract][Full Text] [Related]
5. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499 [TBL] [Abstract][Full Text] [Related]
6. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046 [TBL] [Abstract][Full Text] [Related]
7. Biochemical and functional study of antithrombin III in newborn infants. McDonald MM; Hathaway WE; Reeve EB; Leonard BD Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806 [TBL] [Abstract][Full Text] [Related]
8. Antithrombotic properties of heparin in a neonatal piglet model of thrombin-induced thrombosis. Schmidt B; Buchanan MR; Ofosu F; Brooker L; Hirsh J; Andrew M Thromb Haemost; 1988 Oct; 60(2):289-92. PubMed ID: 3217922 [TBL] [Abstract][Full Text] [Related]
9. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence. Bohner J; von Pape KW; Blaurock M Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789 [TBL] [Abstract][Full Text] [Related]
10. Alpha-2-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma. Schmidt B; Mitchell L; Ofosu FA; Andrew M Thromb Haemost; 1989 Dec; 62(4):1074-7. PubMed ID: 2482548 [TBL] [Abstract][Full Text] [Related]
11. Rapid quantitation of plasma heparin and antithrombin III levels for cardiopulmonary bypass monitoring, using fluorometric substrate assays. Savidge GF; Kesteven PJ; Al-Hasani SF; O'Brien PF Thromb Haemost; 1983 Oct; 50(3):745-8. PubMed ID: 6648894 [TBL] [Abstract][Full Text] [Related]
12. [A method of determining heparin in blood plasma based on its antithrombin activity]. Taktashev RE; Suvorova AV; Miller VE; Kolesnikova OI Lab Delo; 1990; (12):59-61. PubMed ID: 1710698 [TBL] [Abstract][Full Text] [Related]
13. Conventional chromogenic heparin assays are influenced by patient's endogenous plasma Antithrombin levels. Mitchell LG; Vegh P Klin Padiatr; 2010 May; 222(3):164-7. PubMed ID: 20514621 [TBL] [Abstract][Full Text] [Related]
14. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Chan AK; Berry LR; Monagle PT; Andrew M Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942 [TBL] [Abstract][Full Text] [Related]
15. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195 [TBL] [Abstract][Full Text] [Related]
16. [Heparin assay in plasma. Comparison of different methods (author's transl)]. Vinazzer H Anaesthesist; 1979 Jun; 28(6):299-303. PubMed ID: 464252 [TBL] [Abstract][Full Text] [Related]
17. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K; Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318 [TBL] [Abstract][Full Text] [Related]
19. Refinement and feasibility testing of a manual micro-method for protamine titration. Newall F; Johnston L; Ignjatovic V; Summerhayes R; Monagle P Int J Lab Hematol; 2009 Aug; 31(4):457-61. PubMed ID: 18371057 [TBL] [Abstract][Full Text] [Related]
20. Effect of continuous low-dose intravenous heparin administered during operation on postoperative measurements of antithrombin III and antifactor Xa. Jennings SA; Heather BP; Greenhalgh RM Surgery; 1984 Sep; 96(3):550-5. PubMed ID: 6474360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]